You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Mendus Q4'23: New milestones
Last year was crucial for Mendus but the company managed to achieve important milestones during the year. Mendus CEO Erik Manting comments highlights of the Q4 and targets for this year in an interview with analyst Antti Siltanen.
Content:
00:00 Introduction
00:20 Mendus in a nutshell
02:33 Focused on maintenance therapy and measurable residual disease
06:27 Cellular immunotherapies
11:08 Safety profile and efficacy of vididencel
14:06 Milestones of 2023 and targets for 2024
17:14 Cash position